Since the early 2000s, the introduction of BCR::ABL1 tyrosine kinase inhibitors (TKIs) has dramatically improved the outcome of patients with CML and is now the cornerstone of CML management. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.